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SUMMARY
Backgrounds
The development of a reliable biomarker for irritable bowel syndrome (IBS) remains
one of the major aims of research in functional gastrointestinal disorders (FGIDs) and
is complicated by the absence of a perfect reference standard. Previous efforts based
on genetic and immune markers have showed promise, but have not been robust.
Aim
To evaluate an extensive panel of gene expression and serology markers combined
with psychological measures in differentiating IBS from health and between sub-
types of IBS.
Methods
Of subjects eligible for analysis (N = 244), 168 met criteria for IBS (60 IBS-C, 57
IBS-D and 51 mixed), while 76 were free of any FGID. A total of 34 markers were
selected based on pathways implicated in pathophysiology of IBS or whole human
genome screening. Psychological measures were recorded that covered anxiety,
depression and somatisation. Models differentiating disease and health were based
on unconditional logistic regression and performance assessed through area under
the receiver-operator characteristic curve (AUC), sensitivity and speciﬁcity.
Results
The performance of a combination of 34 markers was good in differentiating IBS
from health (AUC = 0.81) and was improved considerably with the addition of
four psychological markers (combined AUC = 0.93). Of the 34 markers consid-
ered, discrimination was derived largely from a small subset. Good discrimination
was also obtained between IBS subtypes with the best being observed for IBS-C vs.
IBS-D (AUC = 0.92); however, psychological variables provided almost no incre-
mental discrimination subtypes over biological markers (combined AUC = 0.94).
Conclusions
A combination of gene expression and serological markers in combination with
psychological measures shows exciting progress towards a diagnostic test for IBS
compared with healthy subjects, and to discriminate IBS-C from IBS-D.
Aliment Pharmacol Ther 2014; 39: 426–437
ª 2014 John Wiley & Sons Ltd
doi:10.1111/apt.12608
426
Alimentary Pharmacology and Therapeutics
INTRODUCTION
Irritable bowel syndrome (IBS) is a highly prevalent
functional gastrointestinal disorder affecting 10–15% of
the population in the western countries,1 with a higher
prevalence in women than men. Patients with IBS are
classiﬁed into three major groups according to their
predominant bowel symptoms: constipation-predominant
IBS (IBS-C), diarrhoea-predominant IBS (IBS-D), and
IBS with mixed diarrhoea and constipation (IBS-M).2
In current clinical practice, guidelines suggest that the
diagnosis of IBS should be based on typical symptoms
with judicious exclusion of organic gastrointestinal disor-
ders such as coeliac disease.3, 4 Symptom-based criteria
such as the Rome criteria for diagnosing IBS have been
developed by an international committee of gastroente-
rologists; however, these are not applied consistently in a
clinical practice setting by community gastroenterologists
or primary care physicians.5 Current clinical practice still
leads clinicians to often order a wide variety of tests
before making a conﬁdent diagnosis of IBS, especially in
older patients where the pre-test probability of organic
disease (e.g. colon cancer) is much higher.6
Most of the tests that clinicians may routinely order,
including a complete blood count, serum chemistry,
liver enzymes, thyroid function tests and stool sam-
pling, have very low diagnostic values in patients with
typical IBS symptoms and no alarm features (such as
weight loss, blood in the stool, unexplained iron deﬁ-
ciency anaemia, nocturnal diarrhoea or a family history
of inﬂammatory bowel disease, coeliac sprue or colon
cancer).7 Notably, such testing can confuse because fal-
se-positive results lead to unnecessary diagnostic evalu-
ations, and true-negative results are not necessarily
reassuring for doctor or patient. Challenges of diagnos-
ing IBS are further complicated by the fact that IBS
patients often present with co-existing functional disor-
ders such as functional dyspepsia, ﬁbromyalgia, chronic
pelvic pain or interstitial cystitis. As a result, patients
with IBS visit physicians more often, consume more
medications and undergo more diagnostic tests than
non-IBS patients.8, 9
While the aetiology of this disorder remains obscure,
there is a body of evidence suggesting dysregulation of
several pathophysiological pathways including serotonin
biosynthesis and metabolism,10–12 mast cell inﬁltration
and degranulation,13–17 visceral hypersensitivity, an exag-
gerated stress response, immune activation and bacterial
infection (post-infectious IBS) or microbiota altera-
tions.18–22
Gene expression proﬁling in tissue samples taken
from patients with IBS has been reported using sig-
moid colonic mucosal tissue.23 Although certain gene
expression biomarkers have been recently reported in
the literature, these markers were derived from data
mining of a published inﬂammatory bowel disease
study.24 However, it is unknown whether there exist
‘surrogate’ transcriptional biomarkers in peripheral
blood cells of patients with IBS.
IBS is widely considered to be a heterogenous condi-
tion possibly resulting in a common constellation of
symptoms from multiple distinct pathologies.25 Apart
from the biological pathways discussed already, individu-
als with IBS are also known to suffer elevated levels of
mood disorders (anxiety and depression) compared with
healthy individuals.26, 27 Whether mood disorder lies
antecedent to the onset of IBS or results from the symp-
toms of the disease remain an open question, 28–30
although the biopsychosocial model 31 would suggest a
bidirectional relationship. There is no strong evidence
that we are aware of that IBS subtypes have different
mood proﬁles.
Given the multiple potential pathophysiological aetiol-
ogies of this phenotypically heterogeneous disorder, it is
unlikely that any single diagnostic test or biomarker will
reliably identify subjects with IBS. The poor clinical reli-
ability of using symptom-based criteria alone to diagnose
IBS and the poor diagnostic values of the currently avail-
able routine diagnostic tests justify the development of a
simple but sensitive and speciﬁc assay to assist clinicians
in making a conﬁdent diagnosis of IBS.
A ﬁrst generation blood-based test for IBS comprising
10 serum biomarkers derived from the literature was
reported by Lembo and colleagues32; the panel of 10 bio-
markers had acceptable speciﬁcity (88%), but poor sensi-
tivity (50%) in differentiating IBS from health. No
further studies using this panel have been reported until
now, although it is noted that our study compares IBS
with health, having excluded organic disease, which
stands in contrast to the combination of functional,
organic and healthy subjects that made up the earlier
study sample. Further work using the sample reported
here and based on discovery methods described in this
study employing a pathway-based approach as well as
genome-wide gene expression proﬁling has led to the
identiﬁcation of an additional 24 promising biomarkers.
This study reports the diagnostic efﬁcacy of the com-
bined 34 markers, 10 identiﬁed in the Lembo paper 32
and 24 in this sample.
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We aimed to develop statistical models based on the
entire panel of 34 biomarkers that would reliably and
speciﬁcally differentiate IBS from healthy volunteers and
differentiate IBS subtypes from each other. As a second-
ary aim, we sought to determine whether psychological
measures added incremental beneﬁt in differentiating
IBS subtypes and IBS from health. We hypothesised that
psychological factors would improve differentiation of
IBS from health, but would provide little or no incre-
mental beneﬁt in differentiating IBS subtypes from each
other. This is, to our knowledge, the ﬁrst prospective
study to use gene expression microarrays for identiﬁca-
tion of differentially expressed genes in peripheral blood
samples as potential biomarkers of IBS compared with
healthy subjects, and also the ﬁrst to combine biological
markers with well-established psychological markers to
differentiate IBS from health.
METHODS
Experimental design
A case–control study design was employed with clearly
deﬁned irritable bowel syndrome patients who under-
went intensive investigation to ensure that they were
functional patients rather than patients suffering from
organic gastrointestinal disease as the ‘cases’. The con-
trols were similarly well characterised as not suffering
from clinically relevant gastrointestinal disorder or other
serious disease. This design allows the clearest identiﬁca-
tion of the biomarker panel’s potential in differentiating
irritable bowel syndrome from health.
Patients
IBS patients and healthy volunteers were recruited from
12 US tertiary referral centres as well as 23 community
gastroenterology clinics. All IBS patients had a physician
diagnosis of IBS, met Rome III criteria for IBS and did
not have any other gastrointestinal disorders; however,
dyspepsia or heartburn was not exclusionary. Patients
with extraintestinal functional disorders, organic gastro-
intestinal disorders, or severe anxiety or depression
(HADs score ≥18 for either scale) were all excluded.
Age- and gender-matched healthy volunteers were Rome
III-negative for IBS, did not have chronic gastrointestinal
symptoms, any active infections or signiﬁcant chronic
medical conditions. At the time of blood collection
enrolled patients were not taking medications that are
known to interfere with serotonin metabolism, mast cell
degranulation or other inﬂammatory pathways that were
under investigation. Chronic use of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) was exclusionary
with the exception of prophylactic use of low-dose aspi-
rin (<82 mg). All subjects provided written informed
consent for analysis of their blood samples, including
separate consents for genetic analyses. The protocol was
approved by institutional review boards (IRBs) of the
respective academic institutions or by the central IRB,
BioMed.
Deﬁnition of IBS and IBS subgroups
IBS subjects in this study were required to meet Rome
III criteria 2 and be diagnosed with IBS by experienced
gastroenterologists. In addition, subjects were required
to experience active IBS symptoms more than twice a
week in the month prior to enrolment and be free of
comorbidities reported to be highly prevalent in individ-
uals with IBS,33 including major psychiatric disorders,
as well as other nongastrointestinal functional disorders
such as ﬁbromyalgia, chronic fatigue and chronic pelvic
pain.
Subjects were assigned to the different subgroups of
diarrhoea-predominant (IBS-D), constipation-predomi-
nant (IBS-C) or mixed IBS (IBS-M) based on predomi-
nant bowel habit according to the Rome III subtype
table and scored by the Bristol Stool Form Scale, which
was asked over a 3-month recall period.
Assessment of IBS severity
Subjects with any degree of IBS severity were enrolled in
the study. However, severity was assessed in all IBS sub-
jects via four different measures as there is no consensus
deﬁnition for categorising IBS patients based on severity.
These measures included two validated instruments, the
IBS-Severity Scoring System (IBS-SSS)34 and the Func-
tional Bowel Disease Severity Index (FBDSI)35, as well as
two self-report scales: a self-report of overall IBS severity
(not at all, somewhat, moderately, very or extremely
severe in response to, ‘rate how severe your IBS is?’);
and self-rated pain severity using a 5-point Likert scale
(0 = none, 1 = mild, 2 = moderate, 3 = intense and
4 = severe).
Psychological measures
In addition to excluding subjects with a diagnosis of one
of the excluded comorbidities, all subjects were adminis-
tered the Hospital Anxiety and Depression scale or
HADs 36 to identify and exclude subjects with severe
anxiety or depression at screening (anxiety or depression
score >18). Other psychological measures assessed so-
matisation status using the Patient Health Questionnaire
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15 (PHQ-15) and stress status using the perceived stress
scale (PSS).37 While no subjects were excluded based on
total score on these two scales, the scoring was intended
to allow stratiﬁcation of patients during analyses.
The PHQ-15 assesses the extent to which individuals
are bothered by a range of somatic symptoms. Several of
these symptoms are gastrointestinal and have been
excluded from consideration in this analysis as they may
induce a logical and statistical circularity. Speciﬁcally, for
this analysis, we omitted items ‘a: stomach pain’, ‘d:
menstrual cramps’, ‘l: constipation, loose bowels, diar-
rhea’ and ‘m: nausea, gas or indigestion’ from the
PHQ-15. A total PHQ score was calculated using the
remaining items and is referred to as the PHQ non-GI.
Selection of markers
Original 10 biomarker panel. The original panel of 10
biomarkers reported by Lembo et al. 32 was identiﬁed
using a seven-step procedure that initially considered
more than 60 000 potential biomarkers identiﬁed via lit-
erature searching and then ﬁltered down to 10 candidate
biomarkers through pragmatic considerations around
measurement and demonstrated efﬁcacy in differentiat-
ing IBS patients from controls.32
Gene chip human array. Blood samples were collected
from eight subjects. Samples were prepared according to
the PAXgene RNA preparation protocol. The samples
were grouped by class and the group were blinded prior
to the screening: group 1 contained three IBS-D; group 2
contained two IBS-C; and group 3 contained three
healthy subjects. The screening was performed with Affy-
metric Human Gene 1.0 ST arrays (Affymetrix, Santa
Clara, CA, USA), an oligonucleotide-probe-based gene
array chip containing ~35 000 transcripts, which pro-
vides a comprehensive coverage of the whole human
genome.
Gene array data analysis. Fluorescence intensities were
uploaded to the Array Assist 6.5 and Gene Spring
GX10.0 (Agilent Technologies, Santa Clara, CA, USA)
software. Data were normalised by quantitative normali-
sation, and then transferred logarithmically for further
analysis to determine changes in a particular gene.
Using a threshold of false discovery rate adjusted P
value <0.25 and a fold change >2, we found 228 differ-
entially expressed genes cumulatively. We then per-
formed a hierarchical clustering analysis to explore
whether the gene expression proﬁles of the DEGs can
separate samples into distinct classes. We used all
unmasked probe sets in this analysis.
To select among the 228 differentially expressed genes,
a pair-wise t-test was performed between each pair of
groups. Fold change, P value and FDR-adjusted P value
38 were computed for each probe set on the array in
each comparison. Differentially expressed genes (DEGs)
were deﬁned as those genes that have a FDR-adjusted P
value <0.25 and a fold change >2. 40 DEGs between
IBS-D and healthy volunteers ordered by fold change.
To identify genes that can be used for both IBS-C and
IBS-D subgroup diagnosis, we further selected 26 genes,
which were upregulated in both groups based on >2 fold
changes and P values.
Real-time quantitative PCR validation of selected DEGs.
We further validated the 66 selected genes out of 228 by
qRT-PCR using samples from 27 healthy volunteers, 19
IBS-C, 22 IBS-D and 17 IBS-M patients. Total RNA was
reversed transcribed into cDNA in a 20 lL reaction using
high capacity cDNA reverse transcription kit (Applied
Biosystems, Bedford, MA, USA). cDNA was then diluted
to 200 ng/lL per reaction. Real-time quantitative reverse
transcript-polymerase chain reaction (qRT-PCR) was
performed in duplicates using two sequence-speciﬁc PCR
primers and a TaqMan assay-FAM dye-labelled MGB
probe to validate the microarray data. Assays were run
using 2 9 Taqman gene expression master mixes with
RNase inhibitor on ABI 7900 Fast thermocycler (Applied
Biosystems). FAM dye-labelled b-actin is used as an
endogenous control for normalisation and Ct values were
obtained for both reference and target gene by auto base-
line and auto threshold settings. ΔΔCt method is used to
calculate the % expression.
A panel of 14 genes was subsequently selected based
on the microarray/Taqman results conﬁrmation with ref-
erence to fold change levels and tested again for conﬁr-
mation on samples from 97 healthy volunteers, 72
IBS-C, 82 IBS-D and 71 IBS-M patients.
Statistical methods
Identiﬁcation of biomarkers. As described above, bio-
marker selection therefore comprised multiple
approaches:
(i) Pathway-focused approach targeting pathways
implicated in IBS pathophysiology, which resulted in
identiﬁcation of 10 serological markers from pathways
involved in pain, serotonin metabolism, mast cell activa-
tion and inﬂammation.32
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(ii) Analysis of differentially expressed genes in IBS
and healthy volunteers, which resulted in the identiﬁca-
tion of 14 differentially expressed genes.
The 24 new markers identiﬁed using these approaches
were combined with the originally identiﬁed 10 markers,32
resulting in a set of 34 markers that were used for further
statistical analyses as described below and in Table 1.
Validation of biomarkers
Models have been developed to differentiate IBS from
healthy volunteers and to distinguish between IBS sub-
types, speciﬁcally: (i) IBS from health; (ii) IBS-C from
IBS-D; (iii) IBS-C from IBS-M; and iv) IBS-D from
IBS-M. All models are based on unconditional logistic
regression estimating the probability of a speciﬁc disease
state (i–iv above) based on a panel of 34 biological mark-
ers (biomarkers) all of which are measured on a quantita-
tive scale as described above. For each disease comparison,
the diagnostic performance of three models is reported: (i)
the full model incorporating all 34 potential biomarkers
regardless of statistical signiﬁcance; (ii) four psychological
measures, PHQ (omitting GI items), HAD anxiety and
depression and the perceived stress score) in addition to
the 34 biomarkers; (iii) backward elimination selection of
markers with statistical signiﬁcance at P < 0.05; and (iv)
backward elimination selection of markers and the four
psychological measures with statistical signiﬁcance at
P < 0.05. We regard models (i) and (ii) to be the primary
analyses and models (iii) and (iv) to provide an indication
of many individual markers and psychological factors are
driving the panel’s diagnostic performance.
The performance of the panel of 10 markers originally
reported by Lembo and colleagues 32 is also considered
and results are reported in Table 1.
Model performance is reported in terms of overall
performance through the AUC with 95% conﬁdence
interval and through sensitivity and speciﬁcity assessed
at a threshold probability identiﬁed as the point at which
the separate sensitivity and speciﬁcity curves cross when
both are plotted against diagnostic probability.
Further details of the laboratory methods used to
identify the biological markers used in this study are
provided in an online supplement (Data S1).
RESULTS
The sample consisted of n = 294 individuals of whom
n = 90 were healthy volunteers (HV) free of functional
gastrointestinal disease, while the remaining n = 204 met
Rome III criteria for irritable bowel syndrome (IBS). A
subset of n = 244 individuals have data on all 34
biomarkers and this group has been utilised in all statis-
tical analyses reported, while 25 individuals have values
recorded for 28 markers and a further 25 individuals
have values recorded for only 24 markers. There was no
difference in the missing value pattern across IBS and
health with 82% of IBS subjects having complete data
compared with 84% of the healthy volunteers.
Among the n = 244 subjects utilised in this study, the
IBS group was divided into 60 IBS-C, 57 IBS-D and 51
mixed IBS (IBS-M), and there were n = 76 health volun-
teers. Study groups did not vary substantially with age or
gender (Table 2) except that the IBS-D group was made
up of proportionately fewer females than IBS-C, IBS-M
and healthy volunteers. IBS subgroups did not differ sub-
stantively with respect to any psychological variable
(Table 2). IBS subgroups were also not markedly differ-
ent in average scores on disease severity scales (Table 2).
IBS subjects were, however, elevated compared with
healthy volunteers in anxiety, depression, somatic symp-
tom reporting and measures of functional bowel symp-
toms (Table 2).
Performance of the original panel
Lembo et al. report an AUC of 0.76 for the discrimina-
tion of IBS from health, and the performance of their
panel in the current sample was consistent with that
with an AUC of 0.74 (95% CI 0.68, 0.81). Performance
of this panel in discriminating between subgroups was a
little lower than for IBS from health: IBS-C vs. D (0.70,
95% CI 0.61, 0.80), IBS-C vs. M (0.65, 95% CI 0.54,
0.75) and IBS-D vs. M (0.71, 95% CI 0.61, 0.81).
Simple comparisons of IBS and healthy volunteers
Inspection of Table 3 suggests that a small number of bi-
omarkers individually noticeably differentiate the four
study groups.
Panel performance in differentiating IBS from health
A model including all biomarkers provides credible differ-
entiation of IBS from health with an AUC of 0.81
(Table 4, Figure 1) and at a threshold probability of 0.60,
sensitivity is 0.81 (95% CI: 0.75, 0.87) and speciﬁcity is
0.64 (95% CI: 0.54, 0.75). Model selection suggests that a
small subset of markers is responsible for the bulk of this
performance with a sub-panel of 4 markers (histamine,
znf326, rnf26, tTG) yielding an AUC of 0.71 (Table 4).
The addition of four psychological measures to the
full panel provided substantial incremental value with an
AUC of 0.93 and sensitivity and speciﬁcity ≥0.80 at a
probability threshold of 0.70 (Table 4) and this is
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Table 1 | Individual members of the 34 biological markers identiﬁed as potentially discriminatory of IBS from health
and a brief description of each
Description
Original Biomarker panel (from Lembo et al. [32])
Interleukin – 1b (IL – 1b) A pro-inﬂammatory cytokine that plays a central role in inﬂammatory diseases
such as IBD and is known to be downregulated by glucocorticoids released
during stress
Growth-related oncogene – a
(GRO – a)
A chemokine associated with chemotactic migration and activation of
neutrophils, which may be involved in tissue injury in IBD patients
Brain-derived neurotrophic factor
(BDNF)
A nerve growth factor thought to be a regulator of neuronal transmission,
which may play an important stimulant role in long-term regulation of
gastrointestinal motility
Anti-Saccharomyces cerevisiae
antibody (ASCA IgA)
An antibody that may reﬂect a generalised loss of immunotolerance. High
levels of ASCA IgA are frequently found in Chrohn’s Disease patients
Antibody against CBir1 (Anti-CBir1) An antibody against bacterial ﬂagellin. Bacterial ﬂagellin is recognised by cells
of the gut mucosa, which may then activate innate immunity
Anti-human tissue
transglutaminase (tTG)
tTG is a tissue-repair enzyme and the major autoantigen in coeliac disease.
Anti-tTG testing can aid in the diagnosis of coeliac disease
Tumour necrosis factor (TNF) –
like weak inducer of apoptosis
(TWEAK)
A cytokine that controls cellular activities such as proliferation, migration,
differentiation, apoptosis and angiogenesis. TWEAK levels are downregulated
in autoimmune pathologies
Anti-neutrophil cytoplasmic
antibody (ANCA)
Autoantibodies that target antigens present in neutrophils, which have been
identiﬁed in the serum of 50% to 80% of ulcerative colitis patients
Tissue inhibitor of
metalloproteinase – 1 (TIMP-1)
An inhibitor of metalloproteinase (MMPs) that break down extracellular
matrix proteins involved in wound healing, angiogenesis and tumour-cell
metastasis. In the gut, altered TIMP activity can result in tissue destruction,
intestinal barrier function impairment, bacteria inﬂux and excessive immune
response
Neutrophil gelatinase-associated
lipocalin (NGAL)
Belongs to the lipocalin family of proteins. In the viscera, NGAL is involved in
a range of functions including molecular transport and GI mucosal
regeneration
New biomarkers (N = 24) (serological markers and gene expression markers)
Serological Markers (N = 10)
Histamine Released by mast cells and involved in allergic reactions. Histamine can cause
inﬂammation and increased permeability of blood vessels. It causes
constriction of smooth muscle.
PGE2 Prostaglandin E2 (PGE2) is involved in neuronal function, female reproduction,
vascular hypertension, tumorigenesis, kidney function and inﬂammation
Tryptase Can be used as an indicator of mast cell activation. Tryptases are mediators of
asthma and other allergic reactions, and are also involved in several
inﬂammatory disorders
Serotonin Serotonin is a neurotransmitter, derived from tryptophan, involved in brain
function; Serotonin is primarily found in the gut. Serotonin regulates
physiological function such as well-being, appetite, sleep, and pain sensitivity
and gut motility.
Substance P A sensory neuropeptide involved in pain perception. Substance P is also
associated with mood disorders, anxiety and stress
IL-12 IL-12 is an heteromeric cytokine involved in naive T cells development. It
stimulates the production of INF-c and TNF-a by T cells. IL-12 also has anti-
angiogenic activity
IL-10 IL-10 is an anti-inﬂammatory cytokine mainly produced by monocytes, and can
inhibit the synthesis of IFN-c, IL-2, TNFa and GM-CSF
IL-6 IL-6 is a pro-inﬂammatory cytokine. It is an acute phase response cytokine
secreted by T cells and macrophages
IL-8 IL-8 is a chemokine and one of the major mediators of the inﬂammatory
response. IL-8 is produced by several cell types and by macrophages. IL-8 is
chemoattractant, and is also a potent angiogenic factor
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Table 1 | (Continued)
Description
TNF-a TNF-a is mainly produced by macrophages and is found in acute and chronic
inﬂammatory conditions
Gene expression markers (N = 14)
CBFA2T2 Core-binding factor, runt domain, alpha subunit 2; translocated to, 2. Biological
role unknown. (May function as a complex with the chimeric protein RUNX1/
AML1-CBFA2T1/MTG8, which is produced in acute myeloid leukaemia with
the chromosomal translocation t(8,21) potentially repressing AML1-
dependent transcription of G-CSF/CSF-3-dependent cell growth) (GeneCards
description)
CCDC147 Coiled-coil domain containing 147. Biological role unknown.
HSD17B11 Hydroxysteroid (17-beta) dehydrogenase 111. (May participate in androgen
metabolism during steroidogenesis) (Gene Cards deﬁnition)
LDLR The low-density lipoprotein receptor (LDLR) gene family consists of cell
surface proteins involved in receptor-mediated endocytosis of speciﬁc ligands
(GeneCards description)
MAP6D1 Encodes a protein highly similar to the mouse MAP6 domain containing 1
protein. May function as a calmodulin-regulated neuronal protein that binds
and stabilises microtubules (GeneCards deﬁnition)
MICALL1 MICAL-like 1, Cytoskeletal regulator, binds to Rab 13. Participates in the
assembly and activity of tight junctions
RAB7L1 Member RAS oncogene family-like 1. Biological role unknown.
RNF26 Ring ﬁnger protein 26, contains a C3HC5 type of RING ﬁnger, a motif known
to be involved in protein-DNA and protein–protein interactions. (GeneCards
deﬁnition)
RRP7A Ribosomal RNA processing 7 homolog A (S. cerevisiae). Biological role
unknown
SUSD4 Sushi domain containing 4. Biological role unknown
SH3BGRL3 Belongs to the SH3BGr = R family, binds to SH3 domain and has SH3/SH2
adaptor activity
VIPR1 Vasoactive Intestinal Peptide Receptor 1, a gut hormone
WEE1 Biological role unknown. May act as negative regulator of entry into mitosis.
Activity of WEE1 increases during s and G2 phases and decreases during M
Phase
ZNF326 Zinc ﬁnger protein 326, Probable transcriptional activator that may play a role
in neuronal differentiation. (GeneCards deﬁnition)
Table 2 | Demographic psychological characteristics of each disease group and statistical contrasts between *IBS and
health and †global test across IBS subtypes
Characteristic IBS-C (n = 60) IBS-D (n = 57) IBS-M (n = 51) Healthy (n = 76) P* P†
Age (mean, s.d.) 38.8 (12.6) 41.1 (13.6) 37.5 (13.3) 38.8 (12.4) 0.9 0.6
Gender (% female) 86 65 85 79 0.9 0.01
Anxiety score (mean, s.d.) 6.52 (3.89) 6.09 (3.42) 6.22 (3.50) 4.12 (2.67) <0.0001 0.8
Depression score (mean, s.d.) 3.30 (3.98) 3.07 (3.20) 2.41 (2.52) 1.47 (1.85) 0.0002 0.7
Non-GI PHQ score score (mean, s.d.) 5.70 (3.61) 5.81 (3.67) 6.16 (3.32) 1.99 (1.63) <0.0001 0.5
PSS score score (mean, s.d.) 15.12 (7.80) 12.81 (6.36) 15.00 (7.08) 9.01 (5.80) <0.0001 0.3
Total IBS-SSS score (mean) 267.20 (91.64) 250.14 (74.13) 266.24 (78.70) – – 0.1
Total FBDSI score (mean) 53.37 (51.12) 51.84 (40.76) 67.61 (50.71) – – 0.3
* Comparing IBS as one group with health.
† Comparing IBS subtypes.
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reﬂected in the shape of the ROC curve (Figure 2). Of
the four psychological measures, the non-GI PHQ
(excluding GI items) OR = 2.41 (95% CI 1.77, 3.27;
P < 0.0005) and perceived stress OR = 1.12 (95% CI
1.01, 1.23; P = 0.03) were most important. The addition
of the psychological measures to the sub-panel also
improved performance substantially with an AUC of
0.91 and reasonable sensitivity and speciﬁcity, although
only the PHQ reached statistical signiﬁcance. Neither age
nor gender added to the discriminatory performance of
the model once genetic and psychological factors are
taken into account.
The four psychological measures, considered
independent of the biomarkers, provide useful discrimi-
nation between IBS and health with an AUC of 0.86
(95% conﬁdence interval 0.82, 0.91) and sensitivity 0.74
and speciﬁcity 0.75 using as a probability threshold
where the separate sensitivity and speciﬁcity curves cross
when plotted against probability of IBS.
Panel performance in differentiating IBS subtypes
A model including all biomarkers provides good differ-
entiation of IBS-C from IBS-D with an AUC of 0.92
(Table 4) and at a threshold probability of 0.50 achieves
Table 3 | Statistical description of each of the 34 biological markers in IBS subtypes and healthy volunteers
Study group
*P
HV IBS-C IBS-D IBS-M
Mean s.d. N Mean s.d. N Mean s.d. N Mean s.d. N
Histamine 181.04 125.57 76 135.33 74.02 60 176.60 119.09 57 126.35 59.91 51 0.02
PGE2 423.35 320.76 76 413.42 452.32 60 507.95 409.98 57 324.62 215.46 51 0.1
Tryptase 9.00 17.08 76 9.72 20.54 60 7.41 6.98 57 7.15 11.98 51 0.6
Serotonin 239.60 105.95 76 247.22 142.80 60 202.12 100.94 57 202.22 97.75 51 0.1
Substance
P
515.08 221.24 76 569.01 219.28 60 549.70 201.28 57 573.59 187.46 51 0.1
IL12 8.54 51.94 76 3.35 11.71 60 5.38 23.20 57 0.54 1.51 51 0.3
IL10 5.69 24.11 76 2.25 5.81 60 3.99 15.07 57 1.04 2.50 51 0.5
IL6 0.39 0.33 76 0.36 0.33 60 0.42 0.25 57 0.80 1.98 51 0.02
IL8 5.67 5.33 76 5.95 11.41 60 8.38 11.23 57 5.81 6.63 51 0.3
TNF-a 1.78 1.11 76 1.95 1.37 60 1.82 0.54 57 2.58 4.34 51 0.1
CBFA2T2 0.55 0.34 76 0.58 0.28 60 0.67 0.44 57 0.57 0.35 51 0.5
CCDC147 0.02 0.01 76 0.03 0.02 60 0.03 0.02 57 0.03 0.02 51 0.6
HSD17B11 2.38 1.28 76 2.62 1.35 60 2.66 1.45 57 2.45 1.48 51 0.4
LDLR 0.06 0.03 76 0.06 0.03 60 0.06 0.02 57 0.06 0.04 51 0.8
MAP6D1 0.01 0.00 76 0.01 0.00 60 0.01 0.00 57 0.01 0.00 51 0.5
MICALL1 0.27 0.12 76 0.29 0.10 60 0.25 0.10 57 0.27 0.12 51 0.3
RAB7L1 0.36 0.26 76 0.42 0.20 60 0.36 0.19 57 0.36 0.21 51 0.06
RNF26 0.34 0.17 76 0.37 0.14 60 0.38 0.17 57 0.35 0.14 51 0.1
RRP7A 0.57 0.41 76 0.73 0.60 60 0.61 0.40 57 0.58 0.28 51 0.2
SUSD4 0.09 0.09 76 0.12 0.12 60 0.09 0.07 57 0.11 0.10 51 0.04
SH3BGRL3 22.09 8.84 76 23.18 8.07 60 21.99 6.59 57 22.78 7.73 51 0.6
VIPR1 0.36 0.30 76 0.35 0.17 60 0.31 0.14 57 0.36 0.21 51 0.5
WEE1 0.07 0.04 76 0.08 0.05 60 0.06 0.03 57 0.07 0.04 51 0.3
ZNF326 0.31 0.26 76 0.31 0.16 60 0.27 0.12 57 0.28 0.15 51 0.6
ANCA 6.83 5.70 76 8.45 6.49 60 10.26 13.50 57 8.49 7.24 51 0.3
ASCA IgA 7.52 8.59 76 8.58 10.88 60 8.10 12.76 57 7.48 7.72 51 0.6
BDNF 16644.68 4983.28 76 16835.42 5846.83 60 17552.89 5925.02 57 17560.20 5558.95 51 0.9
Anti-CBir1 16.79 20.52 76 13.22 8.75 60 14.35 16.25 57 13.90 11.31 51 >0.9
GRO- a 239.01 208.91 76 413.38 583.09 60 251.01 202.93 57 327.30 288.07 51 0.2
IL1Betan 158.93 194.28 76 171.01 269.50 60 109.88 110.16 57 132.31 135.16 51 0.7
NGAL 139.78 64.82 76 136.61 47.68 60 157.13 46.14 57 151.53 54.93 51 0.01
TMP-1 240.63 45.60 76 238.03 51.55 60 249.45 50.59 57 253.90 69.54 51 0.4
TWEAK 1080.76 443.86 76 1112.27 371.58 60 1221.61 375.27 57 1057.49 401.11 51 0.04
tTG 0.96 4.68 76 0.30 0.27 60 0.29 0.29 57 0.23 0.18 51 0.0002
* P = P value from Kruskal–Wallis test.
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sensitivity of 0.83 (95% CI: 0.74, 0.93) and speciﬁcity of
0.86 (95% CI: 0.77, 0.95). Model selection again suggests
that a small subset of markers is responsible for the bulk
of this performance with a sub-panel of four markers
(histamine, NGAL, micall1, rnf26) yielding an AUC of
0.75 (Table 4). The addition of four psychological mea-
sures provided little incremental value to the diagnostic
performance, raising the AUC to 0.94, although only one
of the measures met the conventional criterion of statis-
Table 4 | Discriminatory performance of statistical models including biological and psychological markers in
differentiating IBS from health and IBS subtypes from each other
Panel IBS vs. health IBS-C vs. IBS-D IBS-C vs. IBS-M IBS-D vs. IBS-M
All markers 0.81 (0.75, 0.87) [34]
Se = 0.81, Sp = 0.64
0.92 (0.87, 0.97) [34]
Se = 0.83, Sp = 0.86
0.85 (0.78, 0.92) [34]
Se = 0.82, Sp = 0.69
0.86 (0.79, 0.93) [34]
Se = 0.84, Sp = 0.67
Minimum set 0.71 (0.64, 0.78) [4]
Se = 0.80, Sp = 0.47
0.75 (0.67, 0.84) [4]
Se = 0.75, Sp = 0.65
0.70 (0.60, 0.79) [4]
Se = 0.88, Sp = 0.45
0.77 (0.68, 0.86) [5]
Se = 0.81, Sp = 0.55
Histamine, znf326,
rnf26, tTG
Histamine, NGALn,
micall1, rnf26
tTG, rab7 l1, IL6, vipr1 Histamine, vipr1, rnf26,
tTG, TWEAK
All markers
and psych2
0.93 (0.90, 0.97) [38]
Se=0.85, Sp=0.88
0.94 (0.90, 0.98) [38]
Se=0.87, Sp=0.84
0.88 (0.82, 0.94) [38]
Se=0.77, Sp=0.75
0.91 (0.86, 0.96) [38]
Se=0.79, Sp=0.84
Minimum set
with psych2
0.91 (0.87, 0.95) [8]
Se=0.82, Sp=0.83
0.81 (0.73, 0.88) [8]
Se=0.77, Sp=0.70
0.75 (0.66, 0.84) [6]
Se=0.72, Sp=0.65
0.80 (0.72, 0.88) [7]
Se=0.79, Sp=0.67
tTG, vipr1, znf326, hsd17bl1,
wee1, TNFa, PSS,
PHQ (non-GI)
Histamine, rnf26, rrp7a,
substance P, NGALn,
rab7 l1, PHQ (non-GI), PSS
IL6, MAP6 dL, vipr1,
rab7 l1, PHQ (non-GI),
HAD depression
GROAn, PGE2, TWEAK,
RNF26, VIPr1, HAD
anxiety, HAD depression
Entries are area followed by 95% conﬁdence interval in parentheses and number of markers included in the model in square
parentheses, se = sensitivity and sp = speciﬁcity.
The full panel of biomarkers provides adequate overall
differentiation of IBS cases from healthy volunteers
(AUC = 0.81). 
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Figure 1 | ROC curve based on full panel for IBS vs.
Health. The full panel of biomarkers provides adequate
overall differentiation of IBS cases from healthy
volunteers (AUC = 0.81).
The full panel of biomarkers in combination with
psychological measures provides strong overall
differentiation of IBS cases from healthy volunteers
(AUC = 0.93).  
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Figure 2 | ROC curve based on full panel with
psychological measures for IBS vs. Health. The full
panel of biomarkers in combination with psychological
measures provides strong overall differentiation of IBS
cases from healthy volunteers (AUC = 0.93).
434 Aliment Pharmacol Ther 2014; 39: 426-437
ª 2014 John Wiley & Sons Ltd
M. P. Jones et al.
tical signiﬁcance (perceived stress; OR = 1.19, 95% CI
1.01, 1.41; P = 0.04).
Adequate differentiation of IBS-C from IBS-M was
achieved using all 34 markers (AUC = 0.85, Table 4)
and again a sub-panel of four markers (tTG, rab7 l1,
IL6, vipr1) appears to account for a large proportion of
the overall panel’s diagnostic performance (Table 4). The
additional of psychological measures provided little
incremental differentiation.
Adequate differentiation of IBS-D from IBS-M was
also achieved using all 34 markers (AUC = 0.86,
Table 4) and a sub-panel of ﬁve markers (histamine,
vipr1, rnf26, tTG, TWEAK) appears to account for a
large proportion of the overall panel’s diagnostic perfor-
mance (Table 4). The addition of psychological measures
provided little incremental differentiation.
Neither age nor gender add to the discriminatory per-
formance of the model with respect to differentiating
any pair of subtypes once genetic and psychological fac-
tors are taken into account.
DISCUSSION
This study set out to assess the performance of a set of
34 potential biological markers of irritable bowel syn-
drome both in terms of differentiating IBS-qualifying
individuals from healthy volunteers and in terms of dif-
ferentiating IBS subtypes from each other. The identiﬁca-
tion of an array of biological markers that would achieve
these differentiations with high sensitivity and speciﬁcity
would transform IBS from a symptom-based diagnosis
of exclusion in clinical practice into a regular medical
disease and provide avenues of investigation into possible
new pathophysiological mechanisms.
The full set of 34 biomarkers was found to provide
encouraging differentiation of IBS from healthy volunteers
and with acceptable sensitivity and speciﬁcity (Table 4).
Furthermore, the addition of four psychological measures
covering mood (anxiety and depression), stress and
non-GI somatic symptoms yielded excellent overall per-
formance (AUC = 0.93) with both sensitivity and speciﬁc-
ity ≥0.85. In the model that included both biological and
psychological markers, a small subset of both appears to
account for the bulk of the model performance, and there-
fore there is scope for future research to create a reduced
panel with minimal reduction in diagnostic performance.
This study was unable to determine whether the incre-
mental value of psychological measures in these models is
indicative of a causal association with IBS or not, but does
suggest a clinically useful role for psychological factors in
the identiﬁcation of IBS. Interestingly, the performance of
the psychological measures alone in differentiating IBS
from health was at least as good and arguably, superior to
that of the biological markers alone. Contrasting the dis-
criminatory performance of the biological markers alone
(AUC = 0.81), psychological markers alone (AUC = 0.86)
and combined biological and psychological markers
(AUC = 0.93) raises some intriguing possibilities regard-
ing the pathogenesis of IBS. Based on this observation, it is
reasonable to hypothesise that the biological and psycho-
logical markers are partly tapping into shared aspects of
IBS pathogenesis. On the other hand, the incremental per-
formance of the combined biological and psychological
markers suggests that these measures may also be identify-
ing distinct aspects of IBS pathogenesis.
The set of biomarkers studied also showed promise in
differentiating IBS subtypes. The data for differentiation
of IBS-C from IBS-D were particularly strong with an
AUC based on the full panel of biomarkers of 0.92
(Table 4). Performance of this set of biomarkers in dif-
ferentiating IBS-C from IBS-M (AUC 0.85) and IBS-D
from IBS-M (AUC 0.86) was also encouraging. The
incremental value of psychological measures in differen-
tiating subtypes appears to be minimal with modest
increases in AUC when psychological measures were
included (Table 4). This suggests that the inﬂuence of
psychological factors is limited to differentiating IBS
from health and that, conditional on having IBS, psycho-
logical factors play little if any role in subtype differenti-
ation.
The subset of markers that were found to provide
statistically independent differentiation of IBS subtypes
varied considerably between subtype comparisons
(Table 4); this provides encouraging although indirect
evidence that distinct mechanisms are being identiﬁed
through the markers selected. For example, four bio-
markers provided discrimination of IBS-C from IBS-D:
histamine, NGAL, micall1 and rnf26 (see table 4).
NGAL belongs to the lipocalin family of proteins; in
the viscera, NGAL is involved in a range of functions
including molecular transport and mucosal regenera-
tion. Similarly, MICAL-like 1 cytoskeletal regulator
binds to Rab 13, and participates in the assembly and
activity of tight junctions. Ring ﬁnger protein 26 is
known to be involved in protein-DNA and protein–
protein interactions, which may also impact on intesti-
nal barrier function. Other data suggest that a leaky
mucosal barrier may be a key abnormality in IBS.39
Histamine may reﬂect mast cell dysfunction, also
known to be a key pathophysiological marker in
IBS.40, 41 The highly novel data presented here in turn
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suggest that IBS subtypes represent entities that are to
some extent biologically distinct.
IBS is likely a heterogenous disorder making identiﬁ-
cation of unique biomarkers potentially extremely chal-
lenging. To maximise the signal to noise ratio and allow
the possible identiﬁcation of unique biomarkers, the
patients enrolled in this study comprised a relatively
homogenous IBS population. Speciﬁcally, they were diag-
nosed by experienced gastroenterologists, met established
symptom-based criteria (Rome III) for IBS, were experi-
encing typical IBS symptoms at the time of study enrol-
ment and were free of comorbidities reported to be
highly prevalent in IBS patients to avoid identiﬁcation of
confounding markers. These comorbidities included psy-
chiatric disorders such as major depression, anxiety or
somatoform disorders, as well as other nongastrointesti-
nal functional disorders such as ﬁbromyalgia, chronic
fatigue and chronic pelvic pain. Healthy volunteers
enrolled as the control group were adults without any ill-
ness, active infection or signiﬁcant medical condition.
This study adds to the mounting evidence that IBS
has an underlying set of biological cause(s).42 Strengths
of the study include well-characterised cases and con-
trols, and novel application of a biomarker panel.
Weaknesses include a relatively small sample size, but
signiﬁcant differences were observed (type II error unli-
kely). Most importantly, while the set of biomarkers
described in this study could distinguish IBS from
health, this is insufﬁcient to conclude whether this par-
ticular set of markers will be useful for diagnosis – this
needs to be conﬁrmed in a study of unselected patients
presenting for care (STARD guidelines).43 In particular,
further research using a larger sample size and more
clinically representative inclusion criteria is needed to
establish that the panel is able to differentiate functional
gastrointestinal disease from organic gastrointestinal
disease.
In conclusion, we have identiﬁed potentially novel bi-
omarkers in IBS, although more work is needed to deter-
mine the diagnostic utility of the panel. Perhaps most
strikingly, a panel of biomarkers alone can discriminate
IBS-C from IBS-D, and psychological measures added
little additional information, providing strong novel evi-
dence that may be distinct and measurable disease states
that can be objectively identiﬁed.
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